PhenomeX to Participate in American Association of Cancer Research Annual Meeting 2023

Rhea-AI Summary

PhenomeX Inc. (Nasdaq: CELL) announced its participation in the AACR Annual Meeting 2023 from April 14-19 in Orlando, Florida. The conference focuses on advancements in cancer science and medicine, highlighting the theme "Advancing the Frontiers of Cancer Science and Medicine." PhenomeX, formed from the merger of Isoplexis and Berkeley Lights (Nasdaq: BLI), will showcase its IsoSpark and Beacon® optofluidic platform technologies at booth #3444. Attendees can see demonstrations and learn about applications that provide insights into cell function relevant to scientific discovery, bioprocessing, and clinical research. Additionally, PhenomeX technologies will feature in nine poster presentations covering various cancer research topics.

EMERYVILLE, Calif., April 7, 2023 /PRNewswire/ -- PhenomeX Inc. (Nasdaq: CELL), the functional cell biology company, today announced its participation at the American Association of Cancer Research (AACR) Annual Meeting 2023 being held from April 14-19 at the Orange County Convention Center in Orlando, Fla. AACR brings together scientists, clinicians, other health care professionals, survivors, patients, and advocates to share the latest advances in cancer science and medicine through this year's meeting theme of "Advancing the Frontiers of Cancer Science and Medicine."

At the conference, PhenomeX, the new company recently formed through the combination of Isoplexis and Berkeley Lights, will showcase its IsoSpark and Beacon® optofluidic platform technologies and workflows in booth #3444. Attendees will have a chance to explore demonstrations of the technologies and learn more about how PhenomeX's applications can provide unparalleled insights into cell function along the continuum of scientific discovery, bioprocessing, translational, and clinical research.

In addition, the AACR Annual Meeting covers the latest advances in cancer through a variety of poster and speaker presentations. This year, PhenomeX technologies are highlighted in nine poster presentations ranging from Polyfunctional Profiles and Cytokine Secretion Activity of Transgenic TCR-T cells and Anti-Cancer Macrophage-Based Cell Therapy to the Identification of Myeloma-Specific T Cell Receptors by Functional Single Cell Interaction Analyses. Some of the presenting abstracts include:

• Dr. Scott Nowicki (UCLA) Abstract | Section 37 / 914/29
• Dr. Alejandro Villagra (Georgetown) Abstract | Section 37 – 900/15
• Dr. Wafik El-Deiry (Brown) Abstract | Section 6 – 2518/26
• Dr. Alejandro Villagra (Georgetown) Abstract | Section 21 – 2880/18
• UT MD Anderson Abstract | Section 22 | 2903/8
• University of Wisconsin, Madison Abstract | Section 25 – 4142/4
• National Institutions of Health (NIH) Abstract | Section 23 – 4103/22

About PhenomeX Inc.

PhenomeX is empowering scientists to leverage the full potential of each cell and drive the next era of functional cell biology that will advance human health. We enable scientists to reveal the most complete insights on cell function and obtain a full view of the behavior of each cell. Our unique suite of proven high-throughput tools and services offer unparalleled resolution and speed, accelerating the insights that are key to advancing discoveries that can profoundly improve the prevention and treatment of disease. Our award-winning platforms are used by researchers across the globe, including those at the top 15 global pharmaceutical companies and approximately 85% of leading U.S. comprehensive cancer centers.

Forward-Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding PhenomeX or its products, they are forward-looking statements reflecting the current beliefs and expectations of management. Such forward-looking statements involve substantial known and unknown risks and uncertainties that relate to future events, and actual results and product performance could differ significantly from those expressed or implied by the forward-looking statements. PhenomeX undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties relating to the Company's growth and continual evolution see the statements in the "Risk Factors" sections, and elsewhere, in our filings with the U.S. Securities and Exchange Commission. 

View original content to download multimedia:https://www.prnewswire.com/news-releases/phenomex-to-participate-in-american-association-of-cancer-research-annual-meeting-2023-301792302.html

SOURCE PhenomeX

FAQ

What is the significance of PhenomeX's participation in the AACR Annual Meeting 2023?

PhenomeX's participation in the AACR Annual Meeting 2023 emphasizes its commitment to advancing cancer research and showcasing innovative technologies that can improve insights into cell biology.

When and where is the AACR Annual Meeting 2023 taking place?

The AACR Annual Meeting 2023 is scheduled from April 14-19, 2023, at the Orange County Convention Center in Orlando, Florida.

What technologies will PhenomeX showcase at the AACR 2023?

At AACR 2023, PhenomeX will showcase its IsoSpark and Beacon® optofluidic platform technologies, which are designed to provide insights into cell function.

How many poster presentations will feature PhenomeX technologies at AACR 2023?

PhenomeX technologies will be highlighted in nine poster presentations covering various topics related to cancer research.

What are the main themes of the AACR Annual Meeting 2023?

The main theme of the AACR Annual Meeting 2023 is "Advancing the Frontiers of Cancer Science and Medicine," focusing on the latest advancements in the field.